Project Grant R01CA304559
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $706K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Georgia Research Foundation, Inc. a $618,236 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on March 24, 2026, with a completion date of February 28, 2031. The award supports the development and preclinical evaluation of calcium nanoparticles (termed ACANPs) designed to enhance radio-immunotherapy efficacy for cancer treatment. The research aims to deliver surface-engineered calcium...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary Cytoagents Inc. received a $1.31 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of CTO1681, an orally available pharmaceutical compound designed to prevent and mitigate cytokine release syndrome (CRS) in multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Project Grant Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with completion targeted for August 31, 2026. The company will develop functional signatures of post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early prediction of patient response in relapsed/refractory large B cell lymphoma (R/RLBCL) treatment. The deliverables center on utilizing...
- Federal Grant Award Summary The National Cancer Institute awarded a $176,040 Project Grant to Massachusetts General Hospital under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. The award funds research to develop engineered CAR-T (Chimeric Antigen Receptor T) cell therapies capable of overcoming the cancer cell glycocalyx barrier, a protective layer that impedes immune cell recognition and destruction of solid tumors. The research addresses a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $399,829 Project Grant to The Washington University on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and mechanistically characterize a novel dendritic cell (DC)-based immunotherapy designated AB7H3-TLR4 CAR-DCs. This research will deliver scientific and technical outputs aimed at overcoming tumor immune tolerance in solid tumors by engineering dendritic cells that express a...
- Federal Grant Award Summary The National Cancer Institute awarded Johns Hopkins University a $591,419 project grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. The award supports the development of low molecular weight theranostics targeting multiple myeloma, a disease characterized by malignant plasma cell expansion in the bone marrow. The research addresses critical gaps in treating therapy-resistant myeloma by developing a...
- Federal Grant Award Summary Mucommune LLC received a $2.29 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded September 16, 2025, with completion targeted for August 31, 2027. The award supports development of in vivo-engineered B7-H3 chimeric antigen receptor T-cell (CAR-T) therapies for pancreatic ductal adenocarcinoma (PDAC) treatment. Rather than employing traditional ex vivo manufacturing processes that are...